Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.
Objective
In this retrospective study, we aimed to compare transplant-related toxicities and hematologic recovery of HDM and Bor-HDM conditioning regimens.
Method
We retrospectively evaluated hematologic recovery and toxicity profile in patients with MM who received AHSCT with either HDM (n = 114) or Bor-HDM (n = 53) conditioning regimen.
Results
Nonhematologic toxicities were comparable between HDM and Bor-HDM conditioning regimen, except mucositis and diarrhea being more frequent in the Bor-HDM group. Neutrophil and platelet engraftment time and duration of hospital stay were significantly shorter for HDM regimen.
Conclusions
In this retrospective analysis, we observed engraftment kinetics and duration of hospitalization were significantly worse in Bor-HDM conditioning regimen with manageable toxicities. Randomized studies are needed to further compare Bor- HDM regimen to HDM in terms of response rates, toxicities, and transplant-related mortality.
KumarSKRajkumarSVDispenzieriAet al.Improved survival in multiple myeloma and the impact of novel therapies. Blood2008; 111: 2516–2520.
2.
Mey UJ, Leitner C, Driessen C, et al. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2015; 34: 217–223.
3.
AttalMHarousseauJStoppaAet al.A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med1996; 335: 91–97.
4.
ChildJMorganGJDaviesFEet al.High-dose chemotherapy with stem cell rescue for multiple myeloma. N Engl J Med2003; 348: 1875–1883.
5.
ShahNThallPFFoxPSet al.Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia2015; 29: 1945–1948.
6.
LahuertaJJMateosMVMartínez-LópezJet al.for the GEM (Grupo Español de MM) and PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatía Maligna) Cooperative Study Groups. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica2010; 95: 1913–1920.
7.
MarkTMReidWNiesvizkyRet al.A Phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant2013; 19: 831–837.
8.
QazilbashMHSalibaRMNietoYet al.Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant2008; 14: 1401–1407.
9.
SharmaMKhanHThallPFet al.A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer2012; 118: 2507–2515.
10.
Ma MH, Yang HH, Parker K, et al. The proteosome inhibitör PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144.
11.
Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteosome inhibitör PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.
12.
MiyamotoTYoshimotoGKamimuraTet al.Combination of high dose melphalan and bortezomib as a conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Int J Hematol2013; 98: 337–345.
13.
HuangWLiJLiHet al.High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma2012; 53: 2507–2510.
14.
RousselMMoreauPHuynhAet al.for the Intergroupe Francophone du Myélome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood2010; 115: 32–37.
15.
LeeSRKimSJParkYet al.Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol2010; 45: 183–187.
16.
LonialSKaufmanJTighiouartMet al.A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study. Clin Cancer Res2010; 16: 5079–5086.
17.
TakezakoNSekiquckiNNagataAet al.Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: A pilot study. Indian J Hematol Blood Transfus2013; 29: 147–151.
18.
ThompsonPAPrinceHMSeymourJFet al.Bortezomib added to high-dose melphalan as pretransplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant2011; 46: 764–765.
19.
GimsingPHjertnerØAbildgaardNet al.Salvage bortezomib-dexamethasone and high dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase 2 trial. Bone Marrow Transplant2015; 50: 1306–1311.
20.
DooNWThompsonPAPrinceHMet al.Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma2013; 54: 1465–1472.
21.
NishihoriTAlekshunTJShainKet al.Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol2012; 157: 553–563.
22.
BladeJSamsonDReeceDet al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol1998; 102: 1115–1123.
23.
PatriarcaFSperottoAFiliCet al.Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma. Haematologica2002; 87: 779–781.
24.
HariPPasquiniMVesoleDH. Cure of multiple myeloma-more hype, less reality. Bone Marrow Transplant2006; 37: 1–18.
25.
WangMDelasalleKFengLet al.CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant2010; 45: 498–504.
26.
VijRKumarSZhangMJet al.Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant2015; 21: 335–341.
27.
KumarSMahmoodSTLacyMQet al.Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant2008; 42: 413–420.
28.
Jimenez-ZepedaVHReeceDETrudelSet al.Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant2015; 50: 204–208.
29.
MoreauPFaconTAttalMet al.Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002; 99: 731–735.
30.
ParmarSRBookoutRShapiroJFet al.Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplantation2014; 49: 761–766.
31.
MiyakoshiSKamiMYujiKet al.Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory mutiple myeloma. Blood2006; 107: 3492–3494.
32.
GotohAOhyashikiKOshimiKet al.Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: A questionnaire-based report from the “lung injury by bortezomib” joint committee of Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol2006; 84: 406–412.
33.
BoyerJEBatraRBAscensaoJLet al.Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood2006; 108: 1113–1113.
34.
SugitaYOhwadaCNagaoYet al.Early-onset severe diffuse alveolar hemorrhage after bortezomib administration suggestive of pulmonary involvement of myeloma cells. J Clin Exp Hematop2015; 55: 163–165.
